Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Octreotide for Diabetic Macular Edema
NCT06881888Phase 1Withdrawn
- Sponsor
- University of Alabama at Birmingham
- Start
- Aug 2026
- Primary completion
- Oct 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised trial of octreotide in diabetic macular edema (DME) (2 arms), sponsored by University of Alabama at Birmingham. Primary endpoints: Macular Central Subfield Thickness at 1 month, Best Corrected Visual Acuity at 1 month and 5 more. Planned start Aug 2026; status: withdrawn.
02
Drugs
octreotide
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT06881888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06881888.